nach oben

Erschienen in:

01.08.2018 | Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Management of VEGF-Targeted Therapy-Induced Hypertension

verfasst von: Stefano Caletti, Anna Paini, Maria Antonietta Coschignano, Carolina De Ciuceis, Matteo Nardin, Roberto Zulli, Maria Lorenza Muiesan, Massimo Salvetti, Damiano Rizzoni

Erschienen in: Current Hypertension Reports | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

From a physiological point of view, VEGFs (vascular endothelial growth factors) and their receptors (VEGFR) play a critical role in vascular development angiogenesis, endothelial function, and vascular tone. On the pathological side, VEGF–VEGFR signaling may induce dysregulated angiogenesis, which contributes to the growth and to the spread of tumors, being essential for neoplastic proliferation and invasion.

Recent Findings

Pharmacological inhibition of VEGF–VEGFR is now a cornerstone in the treatment of many malignancies; however, treatment with VEGF inhibitors is commonly associated with an increase in blood pressure values. This side effect is strictly connected with the mechanism of action of these medications and might represent an index of therapy efficacy.

Summary

The optimal management of this form of hypertension is, at present, not clear. Calcium channel blockers and renin-angiotensin system inhibitors probably represent the most appropriate classes of hypertensive dugs for the treatment of this condition; however, no conclusive data are presently available.

Svilaas T, Lefrandt JD, Gietema JA, Kamphuisen PW. Long-term arterial complications of chemotherapy in patients with cancer. Thromb Res. 2016;140S1:S109–18.CrossRef

De Santis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.CrossRef

Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13:229–36.CrossRefPubMed

De Vos F, Nuver J, Willemse P. Long-term survivors of ovarian malig- nancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage. Eur J Cancer. 2004;40:696–700.CrossRefPubMed

Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–31.CrossRefPubMed

Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20:816–27.CrossRefPubMed

Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer—Childhood Cancer Survivor Study. N Engl J Med. 2006;355:1572–82.CrossRefPubMed

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefPubMed

Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460–8.CrossRefPubMed

10.

Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63:1475–8.CrossRefPubMed

11.

Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–2.CrossRefPubMed

12.

Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186–93.CrossRefPubMed

13.

Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One. 2014;9(7):e101145.CrossRefPubMedPubMedCentral

14.

Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9–17.CrossRefPubMed

15.

Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2013;75:919–30.CrossRefPubMed

16.

Qi WX, Lin F, Sun YJ, Tang LN, He AN, Yao Y, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71:431–9.CrossRefPubMed

17.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMed

18.

Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18:1117.CrossRefPubMed

19.

Fukuda N, Takahari D, Wakatsuk T. Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. Oncotarget. 2018;9:15219–27.PubMedPubMedCentral

20.

Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013;18:273–80.CrossRefPubMedPubMedCentral

21.

Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008;8:880–7.CrossRefPubMedPubMedCentral

22.

Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34:1785–8.CrossRefPubMed

23.

Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–74.CrossRefPubMed

24.

Storkebaum E, Ruiz de Almodovar C, Meens M, Zacchigna S, Mazzone M, Vanhoutte G, et al. Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. Circulation. 2010;122:273–81.CrossRefPubMed

25.

Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691–703.CrossRefPubMedPubMedCentral

26.

Sela S, Itin A, Natanson-Yaron S, Greeneld C, Goldman-Wohl D, Yagel S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res. 2008;102:1566–74.CrossRefPubMed

27.

Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003;111:779–83.CrossRefPubMedPubMedCentral

28.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.CrossRefPubMed

29.

Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753–64.CrossRefPubMed

30.

Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–44.CrossRefPubMed

31.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMed

32.

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–7.CrossRefPubMedPubMedCentral

33.

Syed YY, McKeage K. Aflibercept: a review in metastatic colorectal cancer. Drugs. 2015;75:1435–45.CrossRefPubMed

34.

•• de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60:607–15. A comprehensive review, taking into account available data about the development and management of hypertension during treatment with antiangiogenic drugs. CrossRefPubMed

35.

•• Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens. 2013;31:444–54. An updated review dealing with mechanism underlying the development of hypertension and proteinuria during treatment with antiangiogenic drugs, again focusing on the possible role of endothelin-1. CrossRefPubMed

36.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–5.CrossRefPubMed

37.

Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/ Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999;274:33057–63.CrossRefPubMed

38.

Facemire CS, Nixon AB, Grif ths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652–8.CrossRefPubMed

39.

Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56:1131–6.CrossRefPubMed

40.

Thijs AM, van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, van der Graaf WT, et al. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61:1060–5.CrossRefPubMed

41.

Thijs AM, van Herpen CM, Verweij V, Pertijs J, van den Broek PH, van der Graaf WT, et al. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J Hypertens. 2015;33:2075–82.CrossRefPubMed

42.

Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295–302.CrossRefPubMed

43.

Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675–81.CrossRefPubMed

44.

Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59:151–7.CrossRefPubMed

45.

de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012;25:1118–23.CrossRefPubMed

46.

Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64:1282–9.CrossRefPubMed

47.

Agabiti-Rosei E, Rizzoni D. Microvascular structure as a prognostically relevant endpoint. J Hypertens. 2017;35:914–21.CrossRefPubMed

48.

Rizzoni D, Paini A, Salvetti M, Rossini C, De Ciuceis C, Agabiti-Rosei C, et al. Inhibitors of angiogenesis and blood pressure. Curr Cardiovasc Risk Rep. 2013;7:244–7.CrossRef

49.

Mourad JJ d, Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role for microcirculation. Ann Oncol. 2008;19:927–34.CrossRefPubMed

50.

Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14:3470–6.CrossRefPubMed

51.

Chen DD, Dong YG, Yuan H, Chen AF. Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished anti- oxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension. 2012;59:1037–43.CrossRefPubMed

52.

Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M, et al. VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension. 2018;71:638–47.CrossRefPubMed

53.

•• Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70:220–6. A very recent contribution that provides an up- to-date assessment of the “state of the art.” CrossRefPubMed

54.

Gu JW, Manning RD Jr, Young E, Shparago M, Sartin B, Bailey AP. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol. 2009;297:R142–8.CrossRefPubMedPubMedCentral

55.

Lankhorst S, Baelde HJ, Clahsen-van Groningen MC, Smedts FM, Danser AH, van den Meiracker AH. Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. Nephrol Dial Transplant. 2016;31:914–21.CrossRefPubMed

56.

•• Boursiquot BC, Zabor EC, Glezerman IG, Jaimes EA. Hypertension and VEGF (vascular endothelial growth factor) receptor tyrosine kinase inhibition: effects on renal function. Hypertension. 2017. https://doi.org/10.1161/HYPERTENSIONAHA.117.09275. This recent interesting paper provides evidence that the use of VEGF tyrosine kinase inhibitors does not adversely affect long-term renal function.

57.

Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; azd2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res. 2008;14:3124–31.CrossRefPubMed

58.

• Moslehi J, Pandey AK, Cardio-Oncology BN. Vascular endothelial growth factor inhibitors, salt, and macrophages: a complicated interaction. Hypertension. 2017;69:785–6. An interesting editorial comment on reference 59. CrossRefPubMed

59.

Lankhorst S, Severs D, Markó L, Rakova N, Titze J, Müller DN, et al. Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: role of interstitial sodium accumulation? Hypertension. 2017;69:919–26.CrossRefPubMed

60.

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596–604.CrossRefPubMedPubMedCentral

61.

Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163:156–63.

62.

Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med. 2013;23:104–13.CrossRefPubMedPubMedCentral

63.

•• Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32:852–62. A landmark contribution on the issue addressed by the present review. CrossRefPubMed

64.

• Kalaitzidis RG, Elisaf MS. Uncontrolled hypertension and oncology: clinical tips. Curr Vasc Pharmacol. 2017;16:23–9. Clinical tips on the management of uncontrolled hypertension in oncology. CrossRefPubMed

65.

•• Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018. J Am Soc Hypertens. 2018 Jun;12(6):409-425. https://doi.org/10.1016/j.jash.2018.03.008. A most recent contribution on the issue, also providing some practical hints.

66.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–324.CrossRefPubMed

67.

Rizzoni D, De Ciuceis C, Porteri E, Agabiti-Rosei C, Agabiti-Rosei E. Use of antihypertensive drugs in neoplastic patients. High Blood Press Cardiovasc Prev. 2017;24:127–32.CrossRefPubMed

68.

Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007;27:3465–70.PubMed

69.

Mir OCR, Ropert S, Cabanes L, Blanchet B, Camps S, Billemont B, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Investig New Drugs. 2012;30:702–7.CrossRef

70.

des Guetz G, Uzzan B, Chouahnia K, Morere JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol. 2011;6:197–202.CrossRefPubMed

71.

Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47:1955–61.CrossRefPubMedPubMedCentral

72.

Derosa L, Izzedine H, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncol Rev. 2016;10(2):298.CrossRefPubMedPubMedCentral

73.

McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:2471–9.CrossRefPubMedPubMedCentral

74.

Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer. 2016;114:1313–7.CrossRefPubMedPubMedCentral

75.

Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 2013;16:289–95.CrossRefPubMed

76.

Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14:285–94.CrossRefPubMedPubMedCentral

77.

Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, et al. Effective strategies for management of hyper tension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152–9.CrossRefPubMed

78.

•• van den Meiracker AH, Danser AH. Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition. Hypertension. 2016;68:17–23. The article provides a description of the mechanisms possibly involved in the development of hypertension and renal injury during VEGF signalling inhibition.

79.

Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res. 2005;28:147–53.CrossRefPubMed

80.

Miyajima A, Yazawa S, Kosaka T, Tanaka N, Shirotake S, Mizuno R, et al. Prognostic impact of renin-angiotensin system blockade on renal cell carcinoma after surgery. Ann Surg Oncol. 2015;22:3751–9.CrossRefPubMed

81.

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. Task force members. 2013 ESH/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRefPubMed

82.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–248.CrossRefPubMed

Titel: Management of VEGF-Targeted Therapy-Induced Hypertension
verfasst von: Stefano Caletti
Anna Paini
Maria Antonietta Coschignano
Carolina De Ciuceis
Matteo Nardin
Roberto Zulli
Maria Lorenza Muiesan
Massimo Salvetti
Damiano Rizzoni
Publikationsdatum: 01.08.2018
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 8/2018
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0871-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Arterial Stiffness in Hypertension: an Update

Resistant Hypertension in Pregnancy: How to Manage?

Nurse’s Contribution to Alleviate Non-adherence to Hypertension Treatment

Immigration and Acculturation: Impact on Health and Well-Being of Immigrants

Stress, Genes, and Hypertension. Contribution of the ISIAH Rat Strain Study